Sam Johnson JOHNSON & MONTELEONE, L.L.P. 350 North Ninth Street, Suite 500 Boise, Idaho 83702 Telephone: (208) 331-2100 Facsimile: (208) 947-2424 <u>sam@treasurevalleylawyers.com</u> Idaho State Bar No. 4777

Attorneys for Plaintiffs

# UNITED STATES DISTRICT COURT DISTRICT OF IDAHO

| RONALD GRUNIG and SHANNON<br>GRUNIG, husband and wife,<br>Plaintiffs,                                 | Case No.                             |     |
|---|--------------------------------------|-----|
| v.<br>JOHNSON & JOHNSON, a New Jersey<br>corporation, and ETHICON, INC., a New<br>Jersey corporation, | COMPLAINT AND DEMAND H<br>JURY TRIAL | FOR |
| Defendants.   |                                      |     |

# **COMPLAINT**

COME NOW Plaintiffs, Ronald Grunig and Shannon Grunig, by and through their attorney of record, Sam Johnson of the law firm of Johnson & Monteleone, LLP, and for causes of action against Defendants, hereby Complain and Allege as follows:

# **PARTIES**

1. At all times herein mentioned, Plaintiffs Ronald and Shannon Grunig, husband and wife, were and are citizens and residents of the state of Idaho, and of the United States.

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 2 of 15

2. Defendant Johnson & Johnson was and is a New Jersey corporation doing business in the state of Idaho, with its principal place of business located at One Johnson & Johnson Plaza, New Brunswick, New Jersey.

3. Defendant Johnson & Johnson organizes its subsidiary businesses into individual Business Units to coordinate the development, manufacture, testing, marketing promotion, training, distribution and sale of its products, including but not limited to its hernia repair mesh products. Within Defendant Johnson & Johnson there exist three sectors: (1) medical devices and diagnostics, (2) pharmaceutical, (3) and consumer. Within the medical devices and diagnostic sector are "Business Units" including the "Ethicon Franchise." The Ethicon Franchise was charged by Defendant Johnson & Johnson with the design, development, promotion, marketing, testing, training, distribution and sale of the hernia mesh repair products at issue in this case. The companies comprising the Ethicon Franchise thus remain under the control of Defendant Johnson & Johnson and include, but are not limited to, Ethicon, Inc.

4. Defendant Ethicon, Inc., was and is a wholly owned subsidiary of Defendant Johnson & Johnson. Defendant Ethicon, Inc., was and is a New Jersey corporation, with its principle place of business located in Somerville, New Jersey. Defendant Ethicon, Inc., transacts business in the state of Idaho.

5. Defendant Ethicon, Inc., is a medical device company engaged in the research, development, testing, manufacture, production, marketing, promotion and/or sale of medical devices, including the Proceed Surgical Mesh involved in this action.

6. Defendant Johnson & Johnson, directly and/or through the actions of Defendant Ethicon, Inc., has at all pertinent times been responsible for the research, development, testing, manufacture, production, marketing, promotion, distribution and/or sale of Proceed labeled

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 3 of 15

products.

7. Defendants are individually, jointly and severally liable to Plaintiffs for damages suffered by Plaintiffs arising from the Defendants' design, manufacture, marketing, labeling, sale and placements of its defective mesh products at issue in the instant action, effectuated directly and indirectly through their respective agents, servants, employees and/or owners, all acting within the course and scope of their representative agencies, services, employments and/or ownership.

8. Defendants are vicariously liable for the acts and/or omissions of its employees and/or agents who were at all relevant times hereto acting on behalf of Defendants and within the scope of their employment or agency with Defendants.

# JURISDICTION AND VENUE

9. This Court has subject matter jurisdiction over this action pursuant to 28 U.S.C. § 1332(a), based upon complete diversity of citizenship between Plaintiffs and all Defendants. The amount in controversy well exceeds the sum of \$75,000.00.<sup>1</sup>

10. This Court has personal jurisdiction over each of the Defendants pursuant to the Idaho Long-Arm Statute, Idaho Code § 5-514. Defendants transact business within the state of Idaho, contracted to sell and supply their Proceed products in the state of Idaho, and committed tortious acts and omissions in Idaho. Defendants' tortious acts and omissions caused injury to Plaintiffs in the state of Idaho. Based upon information and belief, Defendants employ sales representatives in the state of Idaho to sell their Proceed products throughout the state, including the Proceed product implanted in Plaintiff Ronald Grunig. Defendants have purposefully engaged in the business of developing, manufacturing, publishing information, marketing, distributing, promoting and/or selling, either directly or indirectly, through third parties, as successor in interest,

<sup>&</sup>lt;sup>1</sup> The medical expenses portion of the claim, alone, exceed the sum of \$80,000.00.

### Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 4 of 15

or other related entities, medical devices including Proceed products in Idaho, for which they derived significant and regular income. The Defendants intended and reasonably expected that their defective mesh products, including Proceed, would be sold and used in Idaho, and could cause injury in Idaho.

11. Venue is proper in this Court pursuant to 28 U.S.C. § 1391(b)(2).

## FACTS COMMON TO ALL COUNTS

12. In October 2010, Plaintiff Ronald Grunig reported to Mercy Medical Center in Nampa, Idaho to undergo a ventral hernia repair. On October 14, 2010, according to the "Operative Report", Dr. Richard Ballantyne, D.O., performed a "laparoscopic assisted ventral incisional hernia repair with PROCEED mesh." The Ethicon PROCEED Surgical Mesh as identified by the Operative Report and the "Product Traceability Label" was a PCDH1 Model, 20 x 25 cm, surgical mesh, bearing LOT No. BKG507, with a use or expiration date of September 2011.

13. Defendants manufactured, sold, and/or distributed the Proceed device to Plaintiff, through his medical providers, to be used for treatment during the aforementioned hernia repair.

14. After several days of worsening symptoms, including nausea, vomiting, pain and discomfort, and abdominal distension, Plaintiff reported to the Emergency Room at Saint Alphonsus Medical Center – Nampa, on July 16, 2017. Plaintiff was diagnosed with a bowel obstruction and admitted into the hospital.

15. Roughly one week later, on or about July 24, 2017, Plaintiff was taken to the Operative Suite of the hospital where Dr. Forrest Fredline, D.O., performed an exploratory "laparotomy with lysis of adhesions." It is noted in the operative report that at "the time of surgery, there was noted to be dense inflammatory attachment between a distal loop of the small bowel and

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 5 of 15

the anterior abdominal wall mesh." When describing the procedure, the surgeon stated how the "bowel was slowly dissected off of the underlying mesh" and describes the "removal of a portion of the mesh . . . ."

16. Defendants were responsible for the research, design, development, testing, manufacture, production, marketing, promotion, distribution and sale of Proceed, including the provisions of warnings and instructions concerning the product.

17. Among the intended purposes for which Defendants designed, manufactured and sold Proceed was use by surgeons for hernia repair surgeries, the purpose for which the Proceed was implanted in Plaintiff Ronald Grunig.

18. Defendants represented to Plaintiff and Plaintiff's physicians that Proceed was a safe and effective product for hernia repair.

19. Defendants' Proceed was defectively designed and/or manufactured, was not reasonably safe for its intended use in hernia repair, and the risks of the design outweighed any potential benefits associated with the design. As a result of the defective design and/or manufacture of the Proceed, there was an unreasonable risk of severe adverse reactions to the mesh or mesh components including: chronic pain; recurrence of hernia; foreign body response; rejection; infection; inadequate or failure of incorporation/ingrowth; migration; scarification; deformation of mesh; improper wound healing; excessive and chronic inflammation; adhesions to internal organs; erosion; abscess; fistula formation; granulomatous response; seroma formation; nerve damage; tissue damage and/or death; and other complications.

20. Proceed has a unique design incorporating a layer of oxidized regenerated cellulose (ORC) over a layer of polydioxanone, which in turn coats a polypropylene mesh. Based upon information and belief, this design is not used in any other hernia repair product sold in the United

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 6 of 15

States. The multi-layer coating was represented and promoted by the Defendants to prevent or minimize adhesion and inflammation and to facilitate incorporation of the mesh into the body, but it did not. Instead, the multi-layer coating prevented adequate incorporation of the mesh into the body and caused or contributed to an intense inflammatory and chronic foreign body response resulting in an adverse tissue reaction including damage to surrounding tissue in the form of sclerotic, granulomatous and/or fibrotic tissue and improper healing.

21. The ORC layer of the Proceed has a tendency to delaminate from the other layers of the mesh, resulting in an air pocket, which leads to the formation of a seroma as the body fills the air pocket with fluid. Seroma formation increases the risk of infection, abscess formation and other complications.

22. When affixed to the body's tissue, the impermeable multi-layer coating of the Proceed prevents fluid escape, which leads to seroma formation, and which in turn can cause infection, abscess formation and other complications.

23. The multi-layer coating provides a breeding ground for bacteria in which the bacteria cannot be eliminated by the body's immune response, which allows infection to proliferate.

24. The multi-layer coating of Defendants' Proceed is cytotoxic, immunogenic, and not biocompatible, which causes or contributes to complications such as delayed wound healing, inflammation, foreign body response, rejection, infection, and other complications.

25. Defendants knew or should have known of the cytotoxic and immunogenic properties of the multi-layer coating of the Proceed prior to introducing it into the stream of commerce.

26. When the multi-layer coating of the Proceed is disrupted, delaminates, and/or

#### Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 7 of 15

degrades, the "naked" polypropylene mesh is exposed to the adjoining tissue and viscera, and can become adhered to organs, cause damage to organs, and potentiate fistula formation.

27. These manufacturing and design defects associated with the Proceed were directly and proximately related to the injuries suffered by Plaintiff Ronald Grunig.

28. Neither Plaintiff Ronald Grunig nor his implanting physician were adequately warned or informed by Defendants of the defective and dangerous nature of Proceed. Moreover, neither Plaintiff Ronald Grunig nor his implanting physician were adequately warned or informed by Defendants of the risks associated with the Proceed or the frequency, severity, or duration of such risks.

29. The Proceed implanted in Plaintiff Ronald Grunig failed to reasonably perform as intended. The mesh caused serious injury and had to be surgically removed via invasive surgery to repair the hernia that the Proceed was initially implanted to treat.

30. Plaintiff Ronald Grunig's severe adverse reaction, and the necessity for surgical removal of the Proceed, directly and proximately resulted from the defective and dangerous condition of the product and Defendants' defective and inadequate warnings about the risks associated with the product, and the frequency, severity and duration of such risks. Plaintiff has suffered, and will continue to suffer, both physical injury and pain and mental anguish, permanent and severe scarring and disfigurement, and has incurred substantial medical bills already exceeding the sum of **\$80,000.00**, and other expenses, resulting from the defective and dangerous condition of the product and from Defendants' defective and inadequate warnings about the risks associated with the product.

# <u>COUNT I</u> <u>Strict Product Liability: Defective Manufacture</u>

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 8 of 15

31. Plaintiffs incorporate herein by reference the allegations in all prior paragraphs as if fully set forth herein

32. Defendants expected and intended the Proceed product to reach users such as Plaintiff Ronald Grunig in the condition in which the product was sold.

33. The implantation of Proceed in Plaintiff's body was medically reasonable, and was a type of use that Defendants intended and foresaw when it designed, manufactured and sold the product.

34. At the time the Proceed that was implanted in Plaintiff's body, the product was defectively manufactured.

35. Defendants' manufacturing and quality control/assurance non-compliance resulted in the non-conformance of the Proceed implanted in Plaintiff Ronald Grunig with intended manufacturing and design specifications.

36. The multi-layer coating of the Proceed also failed to conform to the Defendants' specifications in terms of shelf-life, thickness, durability, and quality.

37. Upon information and belief, Defendants' utilized adulterated polypropylene to manufacture Proceed.

38. Upon information and belief, Defendants' utilized adulterated cellulose to manufacture the Proceed.

39. As a direct and proximate result of the defective manufacture of the Proceed, Plaintiff suffered injuries and damages as summarized herein.

# <u>COUNT II</u> <u>Strict Product Liability: Defective Design</u>

40. Plaintiffs incorporate herein by reference the allegations in all prior paragraphs as if fully set forth herein.

#### Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 9 of 15

41. At the time the Proceed that was implanted in Plaintiff Ronald Grunig's body, the product was defectively designed. As described above, there was an unreasonable risk that the product would not perform safely and effectively for the purposes for which it was intended, and Defendants failed to design against such dangers, and failed to provide adequate warnings and instructions concerning these risks.

42. Defendants expected and intended the Proceed product to reach users such as Plaintiff in the condition in which the product was sold.

43. The implantation of Proceed in Plaintiff's body was medically reasonable, and was a type of use that Defendants intended and foresaw when it designed, manufactured and sold the product.

44. The risks of the Proceed significantly outweigh any benefits that Defendants contend could be associated with the product. The multi-layer coating prevents tissue from incorporating into the mesh, leading to encapsulation, deformation, scarification and contraction, migration, erosion and rejection. The impermeable multi-layer coating leads to seroma formation, and provides a breeding ground for infection, and protects bacteria from being eliminated by the body's natural immune response.

45. The multi-layer coating of the Proceed, which was marketed, promoted and intended as a barrier against adhesion to the internal organs, was only temporary; it was expected and intended to degrade over time inside the body. Thus, this coating prevented tissue ingrowth in the short term, and degraded in the long-term, eventually leaving the "naked" polypropylene mesh exposed to the internal viscera and tissues. The degradation of this multi-layer coating caused or exacerbated an intense inflammatory and foreign body reaction. Once exposed to the viscera, the polypropylene mesh will inevitably adhere to the viscera, initiating a cascade of

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 10 of 15

adverse consequences. Any purported beneficial purpose of the multi-layer coating (to prevent adhesion to the internal viscera and organs) was non-existent; the product provided no benefit while substantially increasing the risks to the patient.

46. The polypropylene mesh within the defective multi-layer coating of the Proceed was in itself dangerous and defective, particularly when used in the manner intended by Defendants. When implanted adjacent to the intestines and other internal organs, as Defendants intended for Proceed, polypropylene mesh is unreasonably susceptible to adhesion, bowel perforation or erosion, fistula formation and bowel strangulation or hernia incarceration, and other injuries.

47. Proceed is sterilized with gamma irradiation, which oxidizes the cellulose, creating oxidized regenerated cellulose (OP""C). Cellulose is not bioresorbable in humans until it has undergone oxidation. The complex oxidation process often results in non-homogenous materials, parts of which are unable to be bioresorbed.

48. Based upon information and belief, Proceed is the only polypropylene hernia mesh currently on the market to utilize gamma irradiation for sterilization of the entire hernia mesh. Gamma irradiation causes polypropylene to significantly degrade, and the degradation continues for a long time after the actual sterilization event. Gamma irradiation induced polypropylene degradation result in severe embrittlement of the polypropylene.

49. The ORC layer of Proceed is compromised in the presence of blood or where there is prolonged fibrin deposition due to inflammation. Fibrin is able to readily penetrate ORC and gain access to the base polypropylene. It is this fibrin bridging which initiates adhesion formation. The polypropylene component of Proceed incites a chronic inflammatory response, leading to prolonged fibrin deposition.

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 11 of 15

50. The appropriate treatment for complications associated with Proceed involves additional invasive surgery to remove the mesh from the body, thus eliminating any purported benefit that the mesh was intended to provide to the patient.

51. Proceed was designed and intended for intraperitoneal implantation, which involved the product being implanted in contact with the intestines and/or other internal organs, which unnecessarily increased the risks of adhesion, erosion, fistula formation, and other injuries.

52. At the time the Proceed was implanted in Plaintiff, there were safer feasible alternative designs for hernia mesh products that would have prevented the injuries he suffered.

53. The Proceed product cost significantly more than competitive products because of its unique multi-layer coating, even though the multi-layer coating provided no benefit to consumers, and increased the risks to patients implanted with these devices.

54. The Proceed implanted in Plaintiff failed to reasonably perform as intended, and had to be partially surgically removed necessitating further invasive surgery to repair the very issue that the product was intended to repair, and thus provided no benefit to him.

55. As a direct and proximate result of the defective and unreasonably dangerous condition of the product, Plaintiff suffered injuries and damages as summarized herein.

# <u>COUNT III</u> Strict Product Liability: Failure to Warn

56. Plaintiffs incorporate herein by reference the allegations in all prior paragraphs as if fully set forth herein.

57. At the time the Proceed that was implanted in Plaintiff's body, the warnings and instructions provided by Defendants for the Proceed were inadequate and defective. As described above, there was an unreasonable risk that the product would not perform safely and effectively for the purposes for which it was intended, and Defendants failed to design and/or manufacture

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 12 of 15

against such dangers, and failed to provide adequate warnings and instructions concerning these risks.

58. Defendants expected and intended the Proceed product to reach users such as Plaintiff in the condition in which the product was sold.

59. Plaintiff and his physicians were unaware of the defects and dangers of Proceed, and were unaware of the frequency, severity and duration of the defects and risks associated with the Proceed.

60. The Defendants' instructions for use provided with the Proceed expressly understates and misstates the risks known to be associated specifically with the Proceed. Based upon information and belief, no other surgical mesh sold in the United States - and no other "surgically implantable material" - suffers the same serious design flaws as Proceed. No other device or material contains the dangerous and defective multi-layer coating, which itself causes or increases the risks of numerous complications, including prevention of incorporation, increased risk of seroma formation, immunológic response, increased risk for infection, and increased inflammatory reaction and foreign body response. Defendants provided no warning to physicians about the risks or increased risks specifically associated with the unique design of the Proceed.

61. The Defendants' Instructions for Use for the Proceed failed to adequately warn Plaintiff's physicians of numerous risks which Defendants knew or should have known were associated with the Proceed, including the risks of the product's inhibition of tissue incorporation, pain, immunologic response, dehiscence, encapsulation, rejection, migration, scarification, shrinkage/contraction, adhesion to internal organs and viscera, erosion through adjacent tissue and viscera, bowel obstruction, failure of repair/hernia recurrence, or hernia incarceration or strangulation.

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 13 of 15

62. Defendants failed to adequately train or warn Plaintiff or his physicians about the necessity for invasive surgical intervention in the event of complications, or how to properly treat such complications when they occurred.

63. Defendants failed to adequately warn Plaintiff or his physicians that the necessary surgical removal of the Proceed in the event of complications would leave the hernia unrepaired, and would necessitate further medical treatment to attempt to repair the same hernia that the failed Proceed was intended to treat.

64. Defendants represented to physicians, including Plaintiff's physician, that the multi-layer coating would prevent or reduce adhesion, and expressly intended for the Proceed to be implanted in contact with the intestines and internal organs and marketed and promoted the product for said purpose. Defendants failed to warn physicians that the multi-layer coating prevented tissue ingrowth, which is the desired biologic response to an implantable mesh device. Defendants failed to warn physicians that the multi-layer and therefore at best would provide only a temporary adhesion barrier, and when the coating inevitably degraded, the exposed polypropylene would become adhered to the organs or tissue.

65. With respect to the complications that were listed in the Defendants' warnings, Defendants provided no information or warning regarding the frequency, severity and duration of those complications, even though the complications associated with Proceed were more frequent, more severe and lasted longer than those with safer feasible alternative hernia repair treatments.

66. If Plaintiff and/or his physicians had been properly warned of the defects and dangers of Proceed, and of the frequency, severity and duration of the risks associated with the Proceed, Plaintiff would not have consented to allow the Proceed to be implanted in his body, and Plaintiff physicians would not have implanted the Proceed in Plaintiff.

## Case 1:18-cv-00111-BLW Document 1 Filed 03/07/18 Page 14 of 15

67. As a direct and proximate result of the inadequate and defective warnings and instructions, Plaintiff suffered injuries and damages as summarized herein.

# COUNT IV Negligence

68. Plaintiffs incorporate herein by reference the allegations in all prior paragraphs as if fully set forth herein.

69. Defendants had a duty to use reasonable care in designing, testing, inspecting, manufacturing, packaging, labeling, marketing, distributing, and preparing written instructions and warnings for Proceed, but failed to do so.

70. Defendants knew, or in the exercise of reasonable care should have known, that Proceed was defectively and unreasonably designed and/or manufactured, and was unreasonably dangerous and likely to injure patients in whom Proceed was implanted. Defendants knew or should have known that Plaintiff and Plaintiff's physicians were unaware of the dangers and defects inherent in the Proceed.

71. As a direct and proximate result of Defendants' negligence in designing, testing, inspecting, manufacturing, packaging, labeling, marketing, distributing, and preparing written instructions and warnings for Proceed, Plaintiffs suffered injuries and damages as summarized herein.

# <u>COUNT V</u> Loss of Consortium

72. Plaintiffs incorporate herein by reference the allegations in all prior paragraphs as if fully set forth herein.

73. As a direct and proximate result of the above-described injuries sustained by Plaintiff, his wife, Plaintiff Shannon Grunig, has suffered a loss of her husband's consortium,

companionship, society, affection, services and support.

# PRAYER FOR RELIEF

WHEREFORE, Plaintiffs pray for judgment against Defendants as a result of the acts and omissions and conduct of Defendants set forth herein. Plaintiff Ronald Grunig is entitled to recover for his personal injuries; past, present, and future medical and related expenses; and past, present and future mental and physical pain and suffering; and Plaintiff Shannon Grunig is entitled to recover for her loss of consortium and services; and Plaintiffs should be awarded punitive damages.

Plaintiffs demand trial by jury, judgment against Defendants, jointly and severally, for compensatory and punitive damages as well as costs, attorney fees, interest, or any other relief, monetary or equitable, to which they are entitled.

#### **DEMAND FOR JURY TRIAL**

Plaintiffs demand a trial by jury on all issues so triable pursuant to Federal Rule of Civil Procedure 38(b).

DATED: This \_\_\_\_\_ day of March, 2018.

JOHNSON & MONTELEONE, L.L.P.

Mr XPhanAll Sam Johnson Attorney to Plaintiffs

# Case 1:18-cv-00111-BLW Document 1-1 Filed 03/07/18 Page 1 of 2

AO 440 (Rev. 06/12) Summons in a Civil Action

| UNITED STATES DISTRICT COURT       |  |  |  |  |  |
|------------------------------------|--|--|--|--|--|
| District of                        |  |  |  |  |  |
| Plaintiff(s)<br>V.<br>Defendant(s) | )<br>)<br>)<br>)<br>)<br>)<br>)<br>)<br>)<br>)<br>)<br>)<br>)<br>) |  |  |  |  |

# SUMMONS IN A CIVIL ACTION

To: (Defendant's name and address)

A lawsuit has been filed against you.

Within 21 days after service of this summons on you (not counting the day you received it) — or 60 days if you are the United States or a United States agency, or an officer or employee of the United States described in Fed. R. Civ. P. 12 (a)(2) or (3) — you must serve on the plaintiff an answer to the attached complaint or a motion under Rule 12 of the Federal Rules of Civil Procedure. The answer or motion must be served on the plaintiff or plaintiff's attorney, whose name and address are:

If you fail to respond, judgment by default will be entered against you for the relief demanded in the complaint. You also must file your answer or motion with the court.

CLERK OF COURT

Date:

Signature of Clerk or Deputy Clerk

AO 440 (Rev. 06/12) Summons in a Civil Action (Page 2)

Civil Action No.

# **PROOF OF SERVICE**

(This section should not be filed with the court unless required by Fed. R. Civ. P. 4 (l))

|        | This summons for (nam            | ne of individual and title, if any)  |                                 |          |  |  |  |
|--------|----------------------------------|--|---------------------------------|----------|--|--|--|
| was re | ceived by me on (date)           |  |                                 |          |  |  |  |
|        | □ I personally served            | the summons on the individua   | l at (place)                    |          |  |  |  |
|        |                                  | ; or   |                                 |          |  |  |  |
|        | $\Box$ I left the summons        | I left the summons at the individual's residence or usual place of abode with <i>(name)</i>  |                                 |          |  |  |  |
|        | on (date)                        | , a person of suitable age and discretion who resides there,<br>on ( <i>date</i> ), and mailed a copy to the individual's last known address; or |                                 |          |  |  |  |
|        |                                  | ons on (name of individual)  | half of (name of organization)  | , who is |  |  |  |
|        |                                  | accept service of process on be  | on (date)                       | ; or     |  |  |  |
|        | $\Box$ I returned the summ       | nons unexecuted because  |                                 | ; or     |  |  |  |
|        | <b>Other</b> ( <i>specify</i> ): |  |                                 |          |  |  |  |
|        | My fees are \$                   | for travel and \$  | for services, for a total of \$ |          |  |  |  |
|        | I declare under penalty          | of perjury that this information   | on is true.                     |          |  |  |  |
| Date:  |                                  |  |                                 |          |  |  |  |
|        |                                  |  | Server's signature              |          |  |  |  |
|        |                                  |  | Printed name and title          |          |  |  |  |
|        |                                  |  |                                 |          |  |  |  |

Server's address

Additional information regarding attempted service, etc:

JS 44 (Rev. 06/17)

# Case 1:18-cv-00111-BLWIL Deciment 1-2 Eiled 03/07/18 Page 1 of 2

The JS 44 civil cover sheet and the information contained herein neither replace nor supplement the filing and service of pleadings or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. *(SEE INSTRUCTIONS ON NEXT PAGE OF THIS FORM.)* 

| I. (a) PLAINTIFFS   |  |   | DEFENDANTS  |   |   |
|---|--|---|---|---|---|
|   | of First Listed Plaintiff<br>KCEPT IN U.S. PLAINTIFF CA<br>Address, and Telephone Numbe  |   | County of Residence of First Listed Defendant<br>(IN U.S. PLAINTIFF CASES ONLY)<br>NOTE: IN LAND CONDEMNATION CASES, USE THE LOCATION OF<br>THE TRACT OF LAND INVOLVED.<br>Attorneys (If Known)   |   |   |
| II. BASIS OF JURISDI  | CTION (Place an "X" in O   | ne Box Only)  | II. CITIZENSHIP OF P  | RINCIPAL PARTIES  | (Place an "X" in One Box for Plaintifj  |
| 1       U.S. Government       3       Federal Question         Plaintiff       (U.S. Government Not a Party)  |  | (For Diversity Cases Only)<br>PT<br>Citizen of This State   |   |   |   |
| 2 U.S. Government<br>Defendant  | ☐ 4 Diversity<br>(Indicate Citizenshi  | ip of Parties in Item III)  |   | <ul> <li>2 2 Incorporated and H<br/>of Business In A</li> <li>3 3 Foreign Nation</li> </ul>   |   |
|   |  |   | Foreign Country   | 5 D 5 Foreign Nation  |   |
| IV. NATURE OF SUIT  |  | ly)<br>RTS  | FORFEITURE/PENALTY  | Click here for: Nature of BANKRUPTCY  | of Suit Code Descriptions.<br>OTHER STATUTES  |
| <ul> <li>110 Insurance</li> <li>120 Marine</li> <li>130 Miller Act</li> <li>140 Negotiable Instrument</li> <li>150 Recovery of Overpayment &amp; Enforcement of Judgment</li> <li>151 Medicare Act</li> <li>152 Recovery of Defaulted Student Loans (Excludes Veterans)</li> <li>153 Recovery of Overpayment of Veteran's Benefits</li> <li>160 Stockholders' Suits</li> <li>190 Other Contract</li> <li>195 Contract Product Liability</li> <li>196 Franchise</li> </ul> <b>REAL PROPERTY</b> <ul> <li>210 Land Condemnation</li> <li>220 Foreclosure</li> <li>230 Rent Lease &amp; Ejectment</li> <li>240 Torts to Land</li> <li>245 Tort Product Liability</li> <li>290 All Other Real Property</li> </ul> | PERSONAL INJURY         310 Airplane         315 Airplane Product<br>Liability         320 Assault, Libel &<br>Slander         330 Federal Employers'<br>Liability         340 Marine         345 Marine Product<br>Liability         350 Motor Vehicle         355 Motor Vehicle         Product Liability         360 Other Personal<br>Injury         362 Personal Injury -<br>Medical Malpractice         CIVIL RIGHTS         440 Other Civil Rights         441 Voting         442 Employment         445 Amer. w/Disabilities -<br>Employment         446 Amer. w/Disabilities -<br>Other         0ther         448 Education | <ul> <li>PERSONAL INJURY</li> <li>365 Personal Injury -<br/>Product Liability</li> <li>367 Health Care/<br/>Pharmaceutical<br/>Personal Injury</li> <li>368 Asbestos Personal<br/>Injury Product Liability</li> <li>368 Asbestos Personal<br/>Injury Product<br/>Liability</li> <li>PERSONAL PROPERT</li> <li>370 Other Fraud</li> <li>371 Truth in Lending</li> <li>380 Other Personal<br/>Property Damage</li> <li>385 Property Damage<br/>Product Liability</li> <li>PRISONER PETITIONS</li> <li>Habeas Corpus:</li> <li>463 Alien Detainee</li> <li>510 Motions to Vacate<br/>Sentence</li> <li>535 Death Penalty<br/>Other:</li> <li>540 Mandamus &amp; Other</li> <li>550 Civil Rights</li> <li>555 Prison Condition</li> <li>560 Civil Detainee -<br/>Conditions of<br/>Confinement</li> </ul> | □       625 Drug Related Seizure<br>of Property 21 USC 881         □       690 Other         □       710 Fair Labor Standards<br>Act         □       710 Fair Labor Standards<br>Act         □       720 Labor/Management<br>Relations         □       720 Labor/Management<br>Relations         □       740 Railway Labor Act         □       751 Family and Medical<br>Leave Act         □       790 Other Labor Litigation         □       791 Employee Retirement<br>Income Security Act         □       142 Naturalization Application | □       422 Appeal 28 USC 158         □       423 Withdrawal 28 USC 157         □       PROPERTY RIGHTS         □       820 Copyrights         □       830 Patent         □       835 Patent - Abbreviated New Drug Application         □       840 Trademark         SOCIAL SECURITY         □       861 HIA (1395ff)         □       862 Black Lung (923)         □       863 DIWC/DIWW (405(g))         □       865 RSI (405(g))         □       FEDERAL TAX SUITS         □       870 Taxes (U.S. Plaintiff or Defendant)         □       871 IRS—Third Party 26 USC 7609 | <ul> <li>OTTERSTATUTES</li> <li>375 False Claims Act</li> <li>376 Qui Tam (31 USC<br/>3729(a))</li> <li>400 State Reapportionment</li> <li>410 Antitrust</li> <li>430 Banks and Banking</li> <li>450 Commerce</li> <li>460 Deportation</li> <li>470 Racketeer Influenced and<br/>Corrupt Organizations</li> <li>480 Consumer Credit</li> <li>490 Cable/Sat TV</li> <li>850 Securities/Commodities/<br/>Exchange</li> <li>891 Agricultural Acts</li> <li>895 Freedom of Information<br/>Act</li> <li>896 Arbitration</li> <li>899 Administrative Procedure<br/>Act/Review or Appeal of<br/>Agency Decision</li> <li>950 Constitutionality of<br/>State Statutes</li> </ul> |
|   | moved from $\Box$ 3 te Court   | Appellate Court   | (specify)   | r District Litigation<br>Transfer   |   |
| VI. CAUSE OF ACTIO  |  |   | filing (Do not cite jurisdictional stat   | utes unless diversity):   |   |
| VII. REQUESTED IN<br>COMPLAINT:   | CHECK IF THIS<br>UNDER RULE 2  | IS A <b>CLASS ACTION</b><br>3, F.R.Cv.P.  | DEMAND \$   | CHECK YES only<br>JURY DEMAND:  | if demanded in complaint:   |
| VIII. RELATED CASH<br>IF ANY  | E(S) (See instructions):   | HIDGE   |   |   |   |
| DATE  | IF AN I     JUDGE     DOCKET NUMBER       SIGNATURE OF ATTORNEY OF RECORD     SIGNATURE OF ATTORNEY OF RECORD  |   |   |   |   |
| FOR OFFICE USE ONLY   |  |   |   |   |   |
|   | 40UNT  | APPLYING IFP  | JUDGE   | MAG. JUE  | DGE   |

### INSTRUCTIONS FOR ATTORNEYS COMPLETING CIVIL COVER SHEET FORM JS 44

Authority For Civil Cover Sheet

The JS 44 civil cover sheet and the information contained herein neither replaces nor supplements the filings and service of pleading or other papers as required by law, except as provided by local rules of court. This form, approved by the Judicial Conference of the United States in September 1974, is required for the use of the Clerk of Court for the purpose of initiating the civil docket sheet. Consequently, a civil cover sheet is submitted to the Clerk of Court for each civil complaint filed. The attorney filing a case should complete the form as follows:

- **I.(a) Plaintiffs-Defendants.** Enter names (last, first, middle initial) of plaintiff and defendant. If the plaintiff or defendant is a government agency, use only the full name or standard abbreviations. If the plaintiff or defendant is an official within a government agency, identify first the agency and then the official, giving both name and title.
- (b) County of Residence. For each civil case filed, except U.S. plaintiff cases, enter the name of the county where the first listed plaintiff resides at the time of filing. In U.S. plaintiff cases, enter the name of the county in which the first listed defendant resides at the time of filing. (NOTE: In land condemnation cases, the county of residence of the "defendant" is the location of the tract of land involved.)
- (c) Attorneys. Enter the firm name, address, telephone number, and attorney of record. If there are several attorneys, list them on an attachment, noting in this section "(see attachment)".

II. Jurisdiction. The basis of jurisdiction is set forth under Rule 8(a), F.R.Cv.P., which requires that jurisdictions be shown in pleadings. Place an "X" in one of the boxes. If there is more than one basis of jurisdiction, precedence is given in the order shown below. United States plaintiff. (1) Jurisdiction based on 28 U.S.C. 1345 and 1348. Suits by agencies and officers of the United States are included here. United States defendant. (2) When the plaintiff is suing the United States, its officers or agencies, place an "X" in this box.

Federal question. (3) This refers to suits under 28 U.S.C. 1331, where jurisdiction arises under the Constitution of the United States, an amendment to the Constitution, an act of Congress or a treaty of the United States. In cases where the U.S. is a party, the U.S. plaintiff or defendant code takes precedence, and box 1 or 2 should be marked.

Diversity of citizenship. (4) This refers to suits under 28 U.S.C. 1332, where parties are citizens of different states. When Box 4 is checked, the citizenship of the different parties must be checked. (See Section III below; **NOTE: federal question actions take precedence over diversity cases.**)

- **III. Residence (citizenship) of Principal Parties.** This section of the JS 44 is to be completed if diversity of citizenship was indicated above. Mark this section for each principal party.
- **IV.** Nature of Suit. Place an "X" in the appropriate box. If there are multiple nature of suit codes associated with the case, pick the nature of suit code that is most applicable. Click here for: <u>Nature of Suit Code Descriptions</u>.
- V. Origin. Place an "X" in one of the seven boxes.

Original Proceedings. (1) Cases which originate in the United States district courts.

Removed from State Court. (2) Proceedings initiated in state courts may be removed to the district courts under Title 28 U.S.C., Section 1441. When the petition for removal is granted, check this box.

Remanded from Appellate Court. (3) Check this box for cases remanded to the district court for further action. Use the date of remand as the filing date.

Reinstated or Reopened. (4) Check this box for cases reinstated or reopened in the district court. Use the reopening date as the filing date. Transferred from Another District. (5) For cases transferred under Title 28 U.S.C. Section 1404(a). Do not use this for within district transfers or multidistrict litigation transfers.

Multidistrict Litigation – Transfer. (6) Check this box when a multidistrict case is transferred into the district under authority of Title 28 U.S.C. Section 1407.

Multidistrict Litigation – Direct File. (8) Check this box when a multidistrict case is filed in the same district as the Master MDL docket. **PLEASE NOTE THAT THERE IS NOT AN ORIGIN CODE 7.** Origin Code 7 was used for historical records and is no longer relevant due to changes in statue.

- VI. Cause of Action. Report the civil statute directly related to the cause of action and give a brief description of the cause. Do not cite jurisdictional statutes unless diversity. Example: U.S. Civil Statute: 47 USC 553 Brief Description: Unauthorized reception of cable service
- VII. Requested in Complaint. Class Action. Place an "X" in this box if you are filing a class action under Rule 23, F.R.Cv.P. Demand. In this space enter the actual dollar amount being demanded or indicate other demand, such as a preliminary injunction. Jury Demand. Check the appropriate box to indicate whether or not a jury is being demanded.
- VIII. Related Cases. This section of the JS 44 is used to reference related pending cases, if any. If there are related pending cases, insert the docket numbers and the corresponding judge names for such cases.

Date and Attorney Signature. Date and sign the civil cover sheet.